Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Influenza

  Free Subscription


Articles published in Antimicrob Agents Chemother

Retrieve available abstracts of 13 articles:
HTML format
Text format



Single Articles


    September 2018
  1. FARRUKEE R, Zarebski AE, McCaw JM, Bloom JD, et al
    CHARACTERIZATION OF INFLUENZA B VIRUS VARIANTS WITH REDUCED NEURAMINIDASE INHIBITOR SUSCEPTIBILITY.
    Antimicrob Agents Chemother. 2018 Sep 10. pii: AAC.01081.
    PubMed     Text format     Abstract available


    August 2018
  2. ALI SO, Takas T, Nyborg A, Shoemaker K, et al
    Evaluation of MEDI8852, an Anti-Influenza A Monoclonal Antibody, in Treating Acute Uncomplicated Influenza.
    Antimicrob Agents Chemother. 2018 Aug 27. pii: AAC.00694.
    PubMed     Text format     Abstract available


    June 2018
  3. YOON JJ, Toots M, Lee S, Lee ME, et al
    Orally Efficacious Broad-Spectrum Ribonucleoside Analog Inhibitor of Influenza and Respiratory Syncytial Viruses.
    Antimicrob Agents Chemother. 2018 Jun 11. pii: AAC.00766.
    PubMed     Text format     Abstract available


    March 2018
  4. VIGIL A, Estelles A, Kauvar LM, Johnson SK, et al
    Native human monoclonal antibodies with potent cross-lineage neutralization of influenza B viruses.
    Antimicrob Agents Chemother. 2018 Mar 5. pii: AAC.02269.
    PubMed     Text format     Abstract available


    January 2018
  5. MCBRIDE JM, Lim JJ, Burgess T, Deng R, et al
    Reply to Hunsberger and Memoli, "Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat".
    Antimicrob Agents Chemother. 2017;62.
    PubMed     Text format    


  6. HUNSBERGER S, Memoli MJ
    Efficacy Analysis in Healthy-Volunteer Influenza Challenge Trials: Intention To Treat.
    Antimicrob Agents Chemother. 2017;62.
    PubMed     Text format    


    November 2017
  7. TSUJI BT, Fisher J, Boadi-Yeboah R, Holden PN, et al
    Azithromycin Pharmacodynamics against 'Persistent' Haemophilus influenza in Chronic Obstructive Pulmonary Disease.
    Antimicrob Agents Chemother. 2017 Nov 27. pii: AAC.01995.
    PubMed     Text format     Abstract available


    August 2017
  8. MCBRIDE JM, Lim JJ, Burgess T, Deng R, et al
    Safety and Efficacy of MHAA4549A, a Broadly Neutralizing Monoclonal Antibody, in a Human Influenza A Challenge Model: A Phase 2 Randomized Trial.
    Antimicrob Agents Chemother. 2017 Aug 14. pii: AAC.01154.
    PubMed     Text format     Abstract available


    May 2017
  9. LIM JJ, Derby MA, Zhang Y, Deng R, et al
    A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending-Dose Study to Investigate the Safety, Tolerability, and Pharmacokinetics of an Anti-Influenza B Monoclonal Antibody, MHAB5553A, in Healthy Volunteers.
    Antimicrob Agents Chemother. 2017 May 30. pii: AAC.00279.
    PubMed     Text format     Abstract available


    April 2017
  10. STAROSILA D, Rybalko S, Varbanetz L, Ivanskaya N, et al
    Anti-influenza activity of Bacillus subtilis probiotic strain.
    Antimicrob Agents Chemother. 2017 Apr 17. pii: AAC.00539.
    PubMed     Text format     Abstract available


  11. GAILLARD V, Galloux M, Garcin D, Eleouet JF, et al
    A Short Double-Stapled Peptide Inhibits Respiratory Syncytial Virus Entry and Spreading.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format     Abstract available


    March 2017
  12. GRIFFIN MP, Khan AA, Esser MT, Jensen K, et al
    Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults.
    Antimicrob Agents Chemother. 2017;61.
    PubMed     Text format     Abstract available


    February 2017
  13. JONES JC, Marathe BM, Vogel P, Gasser R, et al
    The PA endonuclease inhibitor RO-7 protects mice from lethal challenge with influenza A or B viruses.
    Antimicrob Agents Chemother. 2017 Feb 13. pii: AAC.02460.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Influenza is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: